Behçet’s disease attacks the eyes in roughly 40% of people who have it, most often as recurrent bouts of uveitis that can threaten sight if left unchecked.1PubMed Central. Behçet’s Disease Uveitis The inflammation tends to involve all layers of the eye at once, a pattern called panuveitis, and it has an unusual tendency to inflame and clot retinal blood vessels. Without modern immunosuppressive treatment, the estimated risk of losing functional vision within five years sits between 10 and 15%, and the consequences fall harder on men and younger patients. What makes Behçet’s ocular disease so tricky is that inflammation can smolder quietly between obvious flares, damaging the retina before anyone realizes it.
How Behçet’s Damages the Eye
The hallmark of Behçet’s eye disease is bilateral, recurrent, non-granulomatous panuveitis combined with occlusive retinal vasculitis.2PubMed Central. Behçet’s Uveitis: Current Diagnostic and Therapeutic Approach “Panuveitis” means inflammation across the front, middle, and back of the eye simultaneously. That pattern is the most common presentation, though some people get inflammation limited to the front chamber (anterior uveitis) or the back of the eye (posterior uveitis).
At the tissue level, the earliest event is a flood of neutrophils, a type of white blood cell that arrives aggressively at sites of inflammation. This neutrophil infiltration, along with swelling of the cells lining blood vessels and a form of vessel-wall damage called fibrinoid necrosis, is seen across all of Behçet’s early lesions, including the ones in the eye.3PubMed. Etiopathogenesis of Behcet’s disease The inflammation breaks down the blood-retinal barrier, a protective boundary that normally keeps plasma proteins and immune cells out of the delicate retinal tissue. Once that barrier fails, fluid and inflammatory cells leak into the retina and vitreous.
The retinal blood vessels take some of the worst damage. Inflammation weakens and clots small arteries and veins in the retina, leading to branch retinal vein occlusions. Over time, the affected vessels narrow and areas of the retina lose their blood supply, which can trigger the growth of abnormal new vessels. Those fragile new vessels are prone to bleeding, sometimes causing vitreous hemorrhage or a distinctive pattern called hemorrhagic periphlebitis, where veins in the retina look like they are encased in blood.4PubMed Central. Ocular Manifestations of Behçet’s Disease: An Update on Diagnostic Challenges and Disease Management The fluid leakage around the macula, the part of the retina responsible for sharp central vision, causes cystoid macular edema, one of the most common reasons people with Behçet’s lose visual acuity.
Who Gets Hit Hardest
Behçet’s eye disease usually appears between the ages of 20 and 30.5PubMed Central. Behçet’s Disease Uveitis In about one in five people, uveitis is the first sign of the disease, showing up before the oral ulcers and other systemic features that eventually confirm the diagnosis. When it is not the initial symptom, it tends to appear two to three years after the first signs of Behçet’s. And even when the disease starts in one eye, the second eye usually becomes involved within a couple of years.
Men consistently fare worse. A study of 880 patients found that damage to the back of the eye and sight-threatening complications were more common in men. The estimated risk of losing useful vision at five years was about 21% for men compared with 10% for women, and at ten years the gap widened to roughly 30% versus 17%.6PubMed. Uveitis in Behçet disease: an analysis of 880 patients The disease also runs a more severe overall course in males, with higher mortality rates concentrated among younger men.7PubMed Central. Gender Differences in Behçet’s Disease Associated Uveitis
Genetics play a role, too. Carrying the HLA-B51 gene variant increases susceptibility to the ocular features of Behçet’s, with the strength of that association varying by geography. Across a large literature survey, HLA-B51 carriers had roughly 1.8 times the odds of developing eye involvement. The association was strongest in East Asian populations, somewhat weaker in Middle Eastern populations, and statistically non-significant in Western European groups.8PubMed. HLA-B51 Carriers are Susceptible to Ocular Symptoms of Behçet Disease and the Association between the Two Becomes Stronger towards the East along the Silk Road: A Literature Survey That geographic gradient follows the ancient Silk Road, which overlaps with the regions where Behçet’s disease is most common.
Diagnosing Eye Involvement
There is no single blood test for Behçet’s disease. The standard diagnostic criteria rely on recognizing a pattern of symptoms: recurrent oral ulcers, genital ulcers, skin lesions, and eye inflammation. The ICBD 2014 criteria are more sensitive than earlier criteria sets, especially in early disease, but they also have a downside: patients with other conditions can sometimes meet the criteria, leading to overdiagnosis. In countries where Behçet’s is common, specialists sometimes rely on their clinical judgment to diagnose patients who present with posterior uveitis or other major organ involvement but do not tick every box on the official criteria.9PubMed Central. Update on the Diagnosis of Behçet’s Disease
When eye involvement is suspected, fluorescein angiography remains a workhorse test. A fluorescent dye is injected into a vein and photographs are taken as the dye circulates through the retinal blood vessels. In one study, half of the eyes examined showed dye leaking from retinal vessels, about 16% showed the characteristic pattern of cystoid macular edema, and a small percentage showed disc swelling or new vessel growth.10PubMed Central. Fluorescein and indocyanine green angiography findings in Behçet’s disease Even in Behçet’s patients with no obvious ocular symptoms, fluorescein angiography can reveal subclinical vessel leakage. One study found that 44% of apparently unaffected eyes had fluorescein leakage at the retinal periphery.11PubMed Central. Ophthalmic findings in Behcet’s disease: Cases without apparent ocular signs That finding matters because it suggests the disease can quietly damage eyes long before a patient notices anything wrong.
What OCT Angiography Is Revealing
Newer non-invasive imaging is changing how doctors monitor Behçet’s eye disease. Optical coherence tomography angiography, or OCTA, can map blood flow in individual retinal layers without injecting dye. Studies comparing Behçet’s patients to healthy controls have found measurable thinning of the ganglion cell layer (the layer closest to the retinal surface) by roughly 15-22%, depending on the sector examined, and reductions in blood vessel density in the deep capillary plexus by about 13-24%.12PubMed. Optical Coherence Tomography Angiography Biomarkers and Microperimetry Features in Behçet’s Uveitis The deep retinal layers appear particularly vulnerable, and certain measurements from those layers are proving quite sensitive at picking up disease. In one analysis, measures of blood-flow area in the deep capillary plexus could distinguish affected from unaffected eyes with about 90% accuracy.13PubMed. Sensitive optical coherence tomography angiography parameters detecting retinal vascular changes in Behcet’s uveitis
Perhaps the most striking finding is that these microvascular changes show up even in Behçet’s patients who have never had a clinical episode of eye inflammation. Perifoveal and peripapillary vessel abnormalities detectable on OCTA appear to precede any symptoms.14Eye. Preclinical ocular features in patients with Behçet’s disease detected by optical coherence tomography angiography If validated, this could eventually allow doctors to catch eye involvement before inflammation becomes obvious, opening a window for earlier treatment.
Treating Acute Flares
When a flare strikes, the priority is to shut down inflammation fast, because every episode risks irreversible retinal damage. High-dose intravenous corticosteroids are the first-line weapon. Studies have shown that intravenous pulse methylprednisolone can reverse severe vision loss during acute Behçet’s retinitis.15PubMed. High-dose intravenous pulse methylprednisolone hemisuccinate in acute Behçet retinitis Adding pulse steroid therapy to standard combination treatment may improve visual acuity more effectively and reduce flare frequency during the first six months.16PubMed. High-dose intravenous steroid pulse therapy in ocular involvement of Behcet’s disease: a pilot double-blind controlled study However, steroids are a short-term solution. Long-term corticosteroid use carries well-known risks, including cataracts and glaucoma, both of which are already complications of Behçet’s eye disease itself.
Keeping Inflammation at Bay
Because the real threat in Behçet’s is cumulative damage from repeated flares, maintenance therapy with immunosuppressive drugs is the backbone of management. Glucocorticoids are typically used to achieve initial remission, and then a steroid-sparing agent takes over for the long haul.17PubMed Central. Advances in the Treatment of Behcet’s Disease Azathioprine is the most widely used first-line maintenance drug, followed by cyclosporine. In one ten-year real-world profile, azathioprine was prescribed in about 37% of cases and cyclosporine in about 29%, with a median treatment duration of just over five years. That sustained therapy cut the average relapse rate roughly in half.18PubMed Central. Systemic Immunomodulatory Therapy in Uveitis Related to Behçet’s Disease: A 10-year Profile
When conventional immunosuppressants fail or the disease is particularly aggressive, biologic drugs come into play. Tumor necrosis factor (TNF) inhibitors such as infliximab and adalimumab are the most studied option. A systematic review and meta-analysis found that biologic drugs significantly reduced steroid requirements and improved visual acuity in patients who had not responded to standard therapy.19PubMed Central. Effects of anti-TNF biologic drugs on uveitis severity in Behçet patients: systematic review and Meta-analysis Data from large case series have also shown that interferon-alpha and TNF inhibitors are effective and safe for refractory major organ involvement, including the eyes.20PubMed Central. Biologic treatments in Behçet’s disease Most biologic prescriptions for ocular Behçet’s come after conventional therapy with steroids and immunosuppressants has already been tried and fallen short.21PubMed Central. Biological therapy for ocular Behçet’s disease with off-label drug prescription in Turkey
There is also growing interest in agents beyond the standard TNF inhibitors. Tocilizumab, which targets a different inflammatory signaling molecule (interleukin-6), has been reported to improve visual acuity and reduce intraocular inflammation in patients who did not respond to other biologics.22Saudi Journal of Ophthalmology. Successful treatment of Behçet’s uveitis with Tocilizumab The evidence for these newer agents is still mostly at the case-report level, but it gives clinicians another option for the hardest-to-treat patients.
Steroid Implants and Local Therapy
Systemic drugs work on the whole body, but sometimes the eye needs direct, local treatment, especially when macular edema is stubbornly persistent. Intravitreal dexamethasone implants (a tiny rod injected inside the eye that slowly releases a corticosteroid over months) have shown promise as an add-on for patients already on systemic therapy. In one study, a single injection improved visual acuity and reduced macular thickness, with the peak vision benefit coming within the first two months. Serious complications were limited to temporary rises in eye pressure in a few patients and cataract surgery needed in two.23PubMed. Efficacy of Dexamethasone Implants in Uveitic Macular Edema in Cases with Behçet Disease
A larger cross-sectional study of 61 patients reinforced those findings. After more than 12 months, the group that received dexamethasone implants alongside systemic treatment had better angiography scores, less vitreous inflammation, and fewer relapses than the group on systemic drugs alone. The implant also allowed patients to reduce their daily oral steroid dose, a meaningful quality-of-life win.24PubMed. Intravitreal dexamethasone implants facilitate the management of refractory Behçet’s uveitis with vasculitis These implants are not a standalone fix; they work best as a bridge, buying time while systemic therapies like biologics ramp up to full effect.
When Surgery Becomes Necessary
Chronic inflammation inside the eye frequently leads to cataracts, and some patients eventually need cataract surgery. The choice of surgical technique matters. In a study of Behçet’s patients, those who had standard cataract extraction (phacoemulsification or extracapsular extraction) achieved vision of 20/200 or better in about 62% of cases, while none of the patients who underwent a more invasive approach combining lensectomy with vitrectomy reached that level. Three of the ten eyes in the more invasive group went on to develop phthisis bulbi, a devastating shrinkage and collapse of the eye, compared with none in the standard surgery group.25Ocular Immunology and Inflammation. Cataract extraction in Behcet’s disease
Vitrectomy, a surgery that removes the gel filling the eye, is sometimes performed when dense vitreous opacification blocks vision. In a small series of nine Behçet’s patients (all male, ages 28-45), five of ten operated eyes gained vision afterward while the other five stayed the same. No eyes developed phthisis, and none had severe postoperative inflammatory flares.26PubMed. Pars plana vitrectomy in ocular Behçet’s disease The general principle is that surgery should be reserved for clear anatomical indications and, ideally, performed when the eye is quiet rather than during active inflammation, since any surgery on a Behçet’s eye risks triggering another flare.
How Prognosis Has Improved
The outlook for Behçet’s eye disease has changed substantially over the past few decades. Before effective immunosuppression was available, blindness rates were grim. With modern treatment, the risk of losing useful vision has been significantly reduced, and it is expected to continue improving as more targeted therapies become available.27PubMed Central. Long-Term Outcomes of Behçet’s Syndrome-Related Uveitis: A Monocentric Italian Experience That said, a 10-15% risk of severe vision loss over five years is still substantial, and it underscores the importance of early, aggressive control of inflammation. Delayed treatment is one of the strongest predictors of a poor visual outcome.
Behçet’s Eye Disease in Children and Adolescents
When Behçet’s strikes before adulthood, the eye disease has some distinctive features. Juvenile-onset patients had non-occlusive retinal vasculitis as their most common presentation (about 80% of eyes), compared with roughly 60% in adult-onset and 53% in late-onset patients. Younger patients also had higher rates of peripheral vessel occlusions, cataracts, and elevated eye pressure.28PubMed Central. Ocular Behçet Disease—Clinical Manifestations, Treatments and Outcomes According to Age at Disease Onset The good news is that visual outcomes at five years were similar across age groups, suggesting that aggressive treatment can offset the inherently more turbulent disease course in children.
Uveitis in juvenile Behçet’s tends to flare frequently and explosively, with sharp drops in vision during attacks. A critical point for pediatricians and parents alike is that early diagnosis matters even when a child does not yet meet all the formal diagnostic criteria for Behçet’s. Starting aggressive immunosuppression early, before the eye accumulates structural damage, can preserve long-term useful vision.29Eye. Uveitis in juvenile Behçet’s disease: clinical course and visual outcome compared with adult patients
The Microbiome Connection
Behçet’s has long been understood as a disease driven by a misfiring immune system in genetically susceptible people, but what actually triggers the misfiring? Research is increasingly pointing toward the body’s microbial communities. Dysbiosis, an imbalance in the oral and gut microbiome, has been found in Behçet’s patients compared with healthy controls.30PubMed Central. Behçet’s Disease-Do Microbiomes and Genetics Collaborate in Pathogenesis? The working hypothesis is that in people who carry genetic risk factors like HLA-B51, certain microbial shifts may be the environmental nudge that activates the inflammatory cascade. This area is still early, and no microbiome-based treatments are in clinical use for Behçet’s, but it helps explain why the disease clusters in certain populations and geographic regions while remaining relatively rare elsewhere.
The Psychological Weight of Losing Vision
Living with a condition that can unpredictably steal your sight exacts a heavy psychological toll. People with Behçet’s uveitis report worse vision-related quality of life, and poorer visual function is linked to higher rates of depression and anxiety. The fear is not just about the current level of vision but about what the next flare might take. Uncertainty over future disease control, dependency on others, and the relentless cycle of treatment and monitoring all compound the burden.31ASIDE Internal Medicine. Psychological Burden in Behçet Disease: A Narrative Review Across Mucocutaneous, Articular, and Ocular Manifestations Clinicians increasingly recognize that addressing this mental health dimension is as important as controlling inflammation, and screening for anxiety and depression should be part of routine care for anyone managing Behçet’s eye disease.